Gilead Sciences and Galapagos NV announced that filgotinib met the primary and major secondary endpoints in the phase 3 FINCH 1 rheumatoid arthritis, as well as the primary endpoint in the phase 3 FINCH 3 study in methotrexate (MTX)-naive rheumatoid arthritis patients.
A systematic review and meta-analysis published in Arthritis Care & Research aimed to assess the duration of efficacy, as well as the onset of adverse events, associated with oral nonsteroidal anti-inflammatory drugs (NSAIDS) used in the treatment of knee osteoarthritis (OA). To investigate these outcomes, researchers conducted a literature search which identified 72 randomized controlled…
